Synergistic Vaccine System for Enhanced Immunity Against SARS-CoV-2

A novel vaccine system integrating replication-defective adenovirus-delivered spike and nucleocapsid immunogens with cutting-edge technologies like AI, IoT, blockchain, and nanomaterials to induce robust immunity against SARS-CoV-2.

The original patent disclosed a method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid immunogens delivered by a replication-defective adenovirus. However, this approach has limitations in terms of tracking vaccine administration and efficacy, optimizing antigen presentation, and personalizing vaccine development. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful and efficient system.

The new inventive concept combines the replication-defective adenovirus-delivered spike and nucleocapsid immunogens with a blockchain-based tracking system for monitoring vaccine administration and efficacy. Additionally, AI-powered analytics optimize antigen presentation and immune response, while a nanomaterial-based adjuvant enhances immune response. An IoT-enabled platform monitors individual immune responses, and a machine learning algorithm predicts optimal vaccine formulations and dosing regimens. This synergistic system enables real-time monitoring of vaccine efficacy and personalized vaccine development.

The new claims introduce novel combinations of technologies, including blockchain-based tracking, AI-powered analytics, nanomaterial-based adjuvants, and IoT-enabled platforms, which are not obvious from the original patent. These integrations provide a non-obvious solution to the limitations of the original patent, enhancing the overall vaccine system.

Alternative embodiments of the inventive concept could include using different types of immunogens, adjuvants, or delivery systems. Additionally, the system could be adapted for use with other diseases or pathogens, or integrated with other technologies like CRISPR or gene editing.

The inventive concept has significant commercial potential in the vaccine development and healthcare industries, particularly in the context of pandemics and emerging diseases. The system's ability to track vaccine administration and efficacy, optimize antigen presentation, and personalize vaccine development could revolutionize the field of vaccine development and improve public health outcomes.